**GlucoTrack, Inc. Announces Pricing of $3.0 Million Public Offering**

On February 4, 2025, GlucoTrack, Inc. (NASDAQ: GCTK) finalized a securities purchase agreement with institutional investors, marking a significant step for the Delaware corporation. The agreement, facilitated by Dawson James Securities, Inc., pertains to the registered direct offering and sale of 2,638,042 shares of the company’s common stock at an offering price of $1.15 per share.

The company plans to raise gross proceeds of approximately $3.03 million from the offering before accounting for placement agent fees and other related expenses. The net proceeds are intended for vital purposes like working capital and general corporate uses. The closing of this offering is scheduled for February 5, 2025.

The Purchase Agreement entails customary representations, warranties, and covenants standard for such transactions. Notably, the company is restricted from certain actions post-offering, including issuing additional shares or engaging in transactions involving Common Stock equivalents. Additionally, directors and executive officers will be bound by lock-up agreements, prohibiting them from selling or transferring their holdings without specific consent.

As part of the offering agreement, Dawson James Securities, Inc. will receive a cash fee equal to 8.0% of the gross proceeds generated through their efforts. To further detail the terms of this transaction, the full Securities Purchase Agreement, Placement Agency Agreement, and Lock-Up Agreements are provided as exhibits with the filing.

Concurrent with this update, GlucoTrack released a press statement on February 4, 2025, disclosing the pricing of the offering. This public communication, though information-rich, should not be considered ‘filed’, unless expressly stated as such by the company.

GlucoTrack, Inc. (NASDAQ: GCTK) remains focused on pioneering technologies for individuals managing diabetes, with the aim to advance continuous blood glucose monitoring. Investors seeking additional details or clarifications regarding the aforementioned filings are advised to refer to the official SEC documentation.

This press release may contain forward-looking statements, acknowledging potential risks and uncertainties associated with the business. Such statements are subject to change and should not be entirely relied upon, as future developments may influence the disclosed information.

For inquiries related to investor relations, kindly contact [email protected]. Media inquiries can be directed to [email protected].

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read GlucoTrack’s 8K filing here.

GlucoTrack Company Profile

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.